Matthew Motteler
Optometrist · Denver, NCNPI 1598835662
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,407 of the $8,731 with a category attached, or 61.9%. 24 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 30.6% of the total. Among optometrist clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $52.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$1K
- Bausch & Lomb Americas Inc.$707
- Bausch & Lomb, A Division Of Bausch Health US, LLC$271
- AbbVie$231
- plus $1K from 18 others
What the payments were for
- Consulting fees$3,21937%
- Speaking & faculty fees$240%
- Travel & lodging$110%
- Food & beverage$5,40762%
- Education$180%
- Entertainment$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 47 | $2,672 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $2,405 |
| Alcon | 34 | $1,131 |
| Bausch & Lomb Americas Inc. | 12 | $707 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $271 |
| AbbVie | 9 | $231 |
| Aerie Pharmaceuticals, Inc. | 2 | $215 |
| Eyevance Pharmaceuticals LLC | 9 | $160 |
| Amgen(2 entities) | 2 | $130 |
| Tarsus Pharmaceuticals, Inc. | 4 | $127 |
| Sun Pharmaceutical Industries Inc. | 7 | $119 |
| Rxsight Inc | 1 | $88 |
| Maculogix, Inc. | 2 | $77 |
| Coopervision Inc. | 1 | $72 |
| Novartis | 3 | $63 |
| Optos, Inc. | 3 | $52 |
| Kala Pharmaceuticals, Inc. | 2 | $40 |
| Biotissue Holdings Inc. | 1 | $36 |
| LKC Technologies, Inc. | 1 | $32 |
| Sight Sciences, Inc. | 1 | $27 |
| Notal Vision, Inc. | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Tearlab Corp | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearScience Lipiflow System$1,800
- Acuvue$552
- One Series Ultra IOL Delivery System$549
- Rhopressa$215
- Rocklatan$215
- Precision 7$131
- INFUSE$124
- TOTAL30$118
- DAILIES$114
- MIEBO$111
- XIIDRA$111
- TEPEZZA$103
How this compares
$8,731 in reported general payments places this provider in the 95th percentile of 1,326 optometrist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $39,120 |
| MieboPerfluorohexyloctane/Pf | 22 | $16,346 |
| LumiganBimatoprost | 13 | $8,910 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $7,268 |
| FlarexFluorometholone Acetate | 14 | $2,003 |
| Latanoprost | 90 | $1,179 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 68 | $619 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 11 | $301 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $284 |
| Timolol Maleate | 14 | $85 |
| Brimonidine Tartrate | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $231 | $48,03046 claims |
| Bausch & Lomb Americas Inc.Miebo | $707 | $16,34622 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $215 | $7,26812 claims |
| Eyevance Pharmaceuticals LLCFlarex | $160 | $2,00314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 optometrist providers in North Carolina.
Other optometrist in Denver
- Crystal BrimerWilmington$920K
- Osama SaidRaleigh$597K
- Ryan CorteAsheville$569K
- Sanjay PatelApex$518K
- Sean SmolenyakRaleigh$512K
- Rachael WrubleBelmont$228K
- Lisa GreeneArden$186K
- Jennifer LyerlyMorrisville$164K
- Timothy PoirierKnightdale$130K
- Randall ThomasConcord$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.